Hunter Syndrome Statistics in US | Key Facts

What Is Hunter Syndrome?

Hunter syndrome — formally known as Mucopolysaccharidosis Type II (MPS II) — is one of the rarest and most devastating inherited metabolic disorders that a family can face. It is caused by a mutation in the IDS gene located on the X chromosome, which leads to a deficiency in the enzyme iduronate-2-sulfatase (I2S). Without this enzyme, the body cannot properly break down large sugar molecules called glycosaminoglycans (GAGs) — specifically heparan sulfate and dermatan sulfate. These molecules accumulate progressively in cells, tissues, and organs throughout the body, causing relentless multisystem damage. Because the IDS gene sits on the X chromosome, Hunter syndrome is an X-linked recessive disorder that affects almost exclusively males — females typically carry the genetic mutation without showing symptoms. The condition was first described in 1917 by Canadian physician Dr. Charles Hunter, who observed two brothers with strikingly similar physical features including enlarged skulls, hernias, coarse facial features, and skeletal deformities. It would take another six decades before the disease was clearly distinguished as genetically distinct from the closely related Hurler syndrome, a milestone finally achieved in 1978.

In the United States, Hunter syndrome is classified as a rare disease, with an estimated ~500 individuals living with the condition — part of a global patient population of approximately 2,000 people worldwide. The disorder is diagnosed predominantly in male children between 18 and 36 months of age, when physical and developmental symptoms become apparent, though a formal diagnosis may take considerably longer given the disease’s rarity and the risk of misdiagnosis as more common conditions like ADHD or orthopedic disorders. There is currently no cure for Hunter syndrome. The only FDA-approved treatment in the United States remains Elaprase (idursulfase), an enzyme replacement therapy (ERT) approved in July 2006 that must be infused intravenously every week for the patient’s entire life — and which, critically, cannot cross the blood-brain barrier, leaving the neurological aspects of the disease largely untreated. That gap in therapeutic capability is now the central focus of the most exciting research in the field, with gene therapy trials underway and the most advanced pipeline candidate — RGX-121 (clemidsogene lanparvovec) by REGENXBIO — having received FDA Priority Review with a PDUFA target date of November 9, 2025.

Interesting Facts about Hunter Syndrome in the US

Source: Hunter syndrome Wikipedia, NCBI StatPearls (Hashmi MS, Gupta V, 2023), Orphanet Journal of Rare Diseases (2021), PMC/NCBI (Mucopolysaccharidosis 100 Years), Grand View Research (2024), IMARC Group Hunter Syndrome Market, Cleveland Clinic, DataM Intelligence, LifeArc (November 2025), Medboundtimes (November 2025), Sabai Global (February 2025), REGENXBIO/FDA

Looking at these numbers together makes the human reality of Hunter syndrome in the United States sharply clear. Just ~500 patients in the entire country. Roughly 1 in every 100,000 to 170,000 male births. A condition so rare that most primary care physicians will never encounter a single case in their career, making the average diagnostic delay a genuine clinical problem — with symptoms like joint stiffness, coarse facial features, developmental delays, and hearing loss frequently attributed to more common conditions before the correct lysosomal storage disorder diagnosis is reached. The over 300–600 known IDS gene mutations driving the disease make genotype-phenotype correlation difficult, which compounds the challenge of prognosis and treatment planning for each individual patient.

The market figures — $1.31 billion globally in 2024 rising to $1.78 billion by 2030 — may seem large for a disease affecting fewer than 2,000 people worldwide, but they reflect the extraordinary cost of treating ultra-rare diseases requiring bespoke biologics. The North American market’s 37.5% global share is driven by the United States’ strong orphan drug reimbursement infrastructure, higher diagnosis rates, and the active pipeline of advanced therapies now moving through FDA review. The January 2025 FDA Breakthrough Therapy Designation for Denali’s DNL310 and the May 2025 FDA Priority Review acceptance of REGENXBIO’s RGX-121 BLA mean that 2025–2026 represents the most significant period of therapeutic advancement in Hunter syndrome’s history since Elaprase’s approval in 2006.

Hunter Syndrome Prevalence & Incidence in the US | Epidemiology Data

Source: Hunter syndrome Wikipedia, NCBI StatPearls (Hashmi & Gupta, July 2023), Cleveland Clinic (MPS II entry), PMC — Mucopolysaccharidosis Type II: One Hundred Years (2020), Orphanet Journal of Rare Diseases (2021), Research & Markets / ResearchAndMarkets (epidemiology report), Takeda MedConnect, IMARC Group

Hunter syndrome’s epidemiology in the United States reflects both the rarity of the condition and the complexity of accurately counting patients in a country with a large, heterogeneous population and — historically — no newborn screening program for MPS disorders. The 2.67 per million overall MPS prevalence calculated for the US in the 2021 Orphanet Journal study is notably lower than Scandinavian countries like Norway (7.06 per million) and Sweden (4.24 per million), which the researchers attribute partly to the US’s greater population diversity and higher birth volume (over 4 million annually) diluting incidence rates, and partly to underdiagnosis in the US primary care system. The absence of newborn screening for MPS II means diagnosis depends entirely on clinicians recognizing the evolving symptom constellation — a process that consistently takes years from first symptoms to confirmed diagnosis.

The geographic distribution of the approximately 500 US patients is not tracked at state level in any publicly available registry, but the clinical picture is consistent: patients are predominantly male children in the toddler-to-early-childhood age range, diagnosed after a parent or specialist notices the progressive coarsening of facial features, joint stiffness, or developmental regression that typically emerges between ages 2 and 4. The higher incidence among Ashkenazi Jewish populations is genetically explained by founder-effect mutations in the IDS gene. The striking contrast with East Asian countries — where MPS II accounts for up to 50% of all mucopolysaccharidoses — versus the US and European rates highlights how population genetics shape rare disease epidemiology in ways that have direct implications for where research, newborn screening programs, and treatment access investments should be targeted.

Hunter Syndrome Symptoms & Clinical Profile | US Medical Data

Source: Cleveland Clinic (Hunter Syndrome MPS II, updated 2023), NCBI StatPearls (Hashmi & Gupta, July 2023), MedicineNet, Sabai Global (February 2025), Hunter syndrome Wikipedia

Hunter syndrome’s clinical presentation makes it one of the most heartbreaking diseases in pediatric medicine precisely because children typically appear normal at birth and develop physically and cognitively for the first two to five years of life — before the accumulating glycosaminoglycans begin causing irreversible damage. The progressive, multisystemic nature of MPS II means that affected children eventually face simultaneous deterioration across virtually every organ system: their joints stiffen, their faces coarsen, their hearing diminishes, their hearts weaken, their airways narrow, and — in the severe neuronopathic form, which affects approximately two-thirds of patients — their cognitive function regresses into what parents often describe as watching childhood dementia unfold in real time. The disease’s two forms — severe and attenuated — sit on a continuum rather than as discrete categories, making individual prognosis highly variable and genotype-phenotype correlation difficult despite over 300–600 known IDS mutations being identified.

The white skin lesions (ivory-colored papules typically appearing on the upper arms, back, and thighs) are a particularly distinctive physical feature of Hunter syndrome that can serve as a clinical diagnostic clue, distinguishing it visually from other mucopolysaccharidoses. The hydrocephalus and behavioral changes that often appear in early childhood — hyperactivity, attention deficits, aggressive behavior, seizures — are frequently misattributed to ADHD or autism spectrum disorder, contributing to the diagnostic delays that remain a significant problem in the US healthcare system. For families receiving a Hunter syndrome diagnosis in the United States in 2025 or 2026, the brutal honest reality is that there is still no cure, the only approved treatment cannot reach the brain, and a child’s prognosis depends significantly on which form of the disease they carry — something that cannot always be predicted with certainty from genetics alone.

Hunter Syndrome Treatment in the US | FDA-Approved & Pipeline Therapies

Source: FDA, Cleveland Clinic, Sabai Global (February 2025), DataM Intelligence (April 2025), LifeArc (November 2025), REGENXBIO BLA announcement (May 2025), Denali press release (January 2025), Labiotech.eu (February 2025), Medboundtimes (November 2025)

The treatment landscape for Hunter syndrome in 2025–2026 is at a genuine inflection point — though for the roughly 500 US patients living with MPS II today, the word “inflection” carries the weight of decades of unmet need. Elaprase has been the only FDA-approved treatment for 19 years, and while it meaningfully reduces glycosaminoglycan levels, improves walking capacity, and shrinks enlarged organs, its fundamental inability to cross the blood-brain barrier means that the majority of the disease’s most devastating consequences — cognitive regression, behavioral deterioration, and the progressive childhood dementia seen in severe cases — remain essentially untreated. The weekly infusion burden — approximately three hours per session, every single week, for the patient’s entire life — places an extraordinary logistical and psychological strain on children and their caregivers.

What has changed in 2025 is the realistic proximity of genuinely better options. REGENXBIO’s RGX-121 — the first gene therapy designed specifically for MPS II — having its BLA accepted for FDA Priority Review with a PDUFA date of November 9, 2025 represents a potential paradigm shift: a one-time intracisternal injection that delivers a functional IDS gene directly to the central nervous system, potentially halting neurological decline in a way Elaprase simply cannot. Denali’s DNL310, with its January 2025 FDA Breakthrough Therapy Designation, offers a next-generation ERT that uses proprietary Enzyme Transport Vehicle technology to ferry the I2S enzyme across the blood-brain barrier — addressing the most critical gap in Elaprase’s efficacy profile. And the extraordinary story of Oliver Chu, a California toddler who in February 2025 became the first human to receive a stem cell gene therapy for Hunter syndrome, with his father reporting “dramatic improvements” in speech, mobility, and cognitive function a year after treatment, has brought real-world hope to a community that has been waiting a very long time for it.

Hunter Syndrome Market & Research Statistics US | 2024–2026

Source: Grand View Research Hunter Syndrome Treatment Market (2024), Fortune Business Insights Hunter Syndrome Treatment Market (2024), IMARC Group Hunter Syndrome Market (2024/2025 report), Research & Markets (2021), DataM Intelligence (April 2025), REGENXBIO BLA announcement (May 2025), Denali Therapeutics (January 2025)

The Hunter syndrome treatment market’s $1.31 billion global valuation in 2024 — and its projected growth to $1.78 billion by 2030 — is driven primarily by the exceptional cost of treating rare genetic disorders and the increasing pace of advanced therapy development rather than by any increase in patient numbers. The North American market’s dominant 37.5% share reflects several US-specific advantages: the FDA’s Orphan Drug Act framework, which provides seven-year market exclusivity, tax credits, and expedited review for rare disease therapies, making the US the world’s most commercially incentivized market for MPS II drug development. Strong private and public health insurance reimbursement for orphan biologics, combined with higher diagnosis rates and more sophisticated specialist networks, means US patients are more likely than counterparts in many other countries to actually receive Elaprase — even at its extraordinary annual cost.

The pipeline activity underway in 2025–2026 will fundamentally reshape this market if regulatory approvals proceed. RGX-121’s potential accelerated approval by the FDA in late 2025 would make it the first gene therapy approved for any mucopolysaccharidosis — a milestone for the broader rare genetic disease field, not just Hunter syndrome. DNL310’s Breakthrough Therapy Designation signals FDA recognition that it may offer substantial improvement over Elaprase, particularly for neurological outcomes. If even one of these candidates achieves US approval and insurance reimbursement, it would transform the standard of care for the approximately 500 US patients currently dependent on a weekly infusion that has been the sole approved option since 2006. For the families of those patients — many of whom have watched children lose the ability to speak, walk, and recognize faces — the years between 2025 and 2030 represent the most consequential window in Hunter syndrome’s history.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE